Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - somatropin - injection, solution - 6.0mg/ml - somatropin 6 mg/1.03 ml

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - somatropin - injection, solution - 12mg/ml - somatropin 12 mg/1.50 ml

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - somatropin - injection, solution - 20mg/ml - somatropin 20 mg/2.5 ml

European Union - English - EMA (European Medicines Agency)

ipsen pharma - somatropin - turner syndrome; dwarfism, pituitary - pituitary and hypothalamic hormones and analogues - long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion.long-term treatment of growth failure associated with turner syndrome.treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation.replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. growth hormone deficiency should be confirmed appropriately prior to treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pegvisomant, quantity: 20 mg - injection, solution - excipient ingredients: water for injections - the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. the treatment goal is to normalise igf-1 levels.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pegvisomant, quantity: 15 mg - injection, solution - excipient ingredients: water for injections - the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. the treatment goal is to normalise igf-1 levels.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pegvisomant, quantity: 10 mg - injection, solution - excipient ingredients: water for injections - the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. the treatment goal is to normalise igf-1 levels.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 0.5 ml - injection, solution - excipient ingredients: - revestive is indicated for the treatment of adult and paediatric patients 2 years of age and above with short bowel syndrome (sbs) who are dependent on parenteral support.,patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 82.26 mg (equivalent: pasireotide, qty 60 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 54.84 mg (equivalent: pasireotide, qty 40 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.